Articles

Executive Order Challenges Childhood Vaccine Schedule: Pharma Implications

An executive order has been signed, initiating an overhaul of the childhood vaccine schedule. This development prompts a critical review of its potential impact on pharmaceutical manufacturers and public health strategies.

HER2 Biology: Driving the Next Wave of Cancer Treatments

Understanding HER2 biology is crucial for developing next-generation cancer therapies. This article delves into how advancements in HER2 research are shaping new treatment paradigms and creating opportunities for pharmaceutical innovation.

Shionogi's Xocova Gains FDA Clearance for COVID-19 Post-Exposure Prevention

Shionogi's COVID-19 antiviral, Xocova, has secured FDA approval for use as a post-exposure preventative measure. This clearance expands the therapeutic landscape for managing SARS-CoV-2 infections.

Executive Order Targets Childhood Vaccine Schedule: What Pharma Needs to Know

A new executive order from the Trump administration aims to overhaul the childhood vaccine schedule, prompting a review of existing recommendations. This development could significantly impact pharmaceutical companies involved in vaccine development and distribution.

CDER Leadership Changes: Navigating the Impact on Pharmaceutical Strategy

Recent leadership changes within the FDA's Center for Drug Evaluation and Research (CDER) signal potential shifts in regulatory priorities and processes. Understanding these changes is crucial for pharmaceutical companies to adapt their business development and regulatory strategies.

UCB's Bimzelx Triumph: Psoriatic Arthritis Market Implications and Competitive Landscape

UCB's Bimzelx (bimekizumab) has secured significant approvals for psoriatic arthritis, demonstrating strong efficacy in head-to-head trials. This success reshapes the competitive landscape and presents key opportunities and challenges for pharmaceutical business development and investment.

Rusan Pharma Secures PMDA GMP Approval, Boosting Global Market Access

Rusan Pharma has successfully obtained Good Manufacturing Practice (GMP) approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its API and Finished Dosage Formulation (FDF) facilities in Ankleshwar and Dehradun. This significant regulatory milestone strengthens the company's global credentials and opens new avenues for market expansion.

Merck's Phase 3 Program: Addressing the Gaps

Merck's Phase 3 program reveals significant gaps that could impact its competitive position. This article analyzes the implications for pharma teams and investors.

GlycoNex Secures PMDA Approval for GNX1021 Phase I Trial

GlycoNex has secured approval from Japan's PMDA for the Phase I trial of GNX1021. This regulatory update has important implications for investors and pharmaceutical teams.

MannKind's Pediatric Expansion: A New Era for Afrezza

MannKind's recent approval of Afrezza for pediatric use marks a significant milestone. This article explores the implications for investors and pharma teams.

Rusan Pharma Launches State-of-the-Art API Facility in Pithampur

Rusan Pharma has unveiled a state-of-the-art facility for Active Pharmaceutical Ingredients (APIs) in Pithampur. This development marks a significant milestone in the company's growth strategy.

Biogen Under Investigation: Implications for the Pharma Industry

Biogen faces scrutiny from the Italian regulator regarding market abuse claims related to multiple sclerosis. This article explores the implications for the pharmaceutical industry.

Rusan Pharma Achieves Global GMP Milestone with PMDA Approval

Rusan Pharma has achieved a significant milestone by obtaining PMDA approval, enhancing its global GMP standing. This article explores the implications for stakeholders.

Kelun-Biotech's ASCO 2026 Presentation: Key Insights on NSCLC

Kelun-Biotech is set to present two registrational studies on non-small cell lung cancer at ASCO 2026, highlighting significant regulatory updates and investment implications.

AbbVie and GSK's Rise in Patient Reputation: Insights for Pharma

AbbVie and GSK have made significant strides in patient reputation in the UK. This article explores the implications for the pharmaceutical industry.

Merck's TroFuse-005 Trial Results: Implications for Investors and Pharma Teams

Merck's TroFuse-005 trial evaluating Sacituzumab Tirumotecan has met primary endpoints of overall survival and progression-free survival in advanced endometrial cancer. This article explores the implications for investors and pharmaceutical teams.

Kelun-Biotech Secures Investigational New Drug Approval for SKB118

Kelun-Biotech has received Investigational New Drug approval from CDE for SKB118, a promising PD-1 x VEGF bispecific antibody. This approval marks a significant milestone for the company and the broader pharmaceutical landscape.

Merck’s Billion-Dollar Bet on TROP2: Regulatory Updates and Implications

Merck's strategic investment in Kelun-Biotech's TROP2 shows promising survival benefits in endometrial cancer. This analysis covers the regulatory updates and their implications for investors.

BMS Leverages AI for Enhanced R&D Efficiency

Bristol Myers Squibb is adopting Anthropic's Claude AI to enhance its drug R&D processes and improve global workflows, signaling a significant shift in pharmaceutical innovation.

Amgen's CFO Departure and Galderma's Strategic Move

Amgen's CFO is retiring, and the company has recruited a Galderma executive with a significant bonus. This article explores the implications for the pharmaceutical landscape.